Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 12/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869377 | 1.00 | ENPP2 (0.56) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL20258257 | 0.92 | ENPP2 (0.66) | ENPP2 | |
| SCHEMBL30146966 | 0.91 | ENPP2 (0.67) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL16739496 | 0.91 | ENPP2 (0.67) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL17508049 | 0.90 | ENPP2 (0.66) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL30146964 | 0.90 | ENPP2 (0.66) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL17508046 | 0.90 | ENPP2 (0.66) | ENPP2PKMSGMS2EIF4ENOTUM | |
| SCHEMBL16739467 | 0.88 | ENPP2 (0.55) | ENPP2PKMEIF4E | |
| SCHEMBL30147019 | 0.88 | ENPP2 (0.55) | ENPP2PKMEIF4E | |
| SCHEMBL16739486 | 0.87 | ENPP2 (0.51) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268668-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2025-04-08 | — | — | US | claimed |
| US-20240189281-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | SABRE THERAPEUTICS LLC (US) | 2024-06-13 | — | — | US | claimed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | claimed |
| US-11344533-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2022-05-31 | — | — | US | claimed |
| EP-3071561-B1 | AUTOTAXIN INHIBITOR COMPOUNDS | SABRE THERAPEUTICS LLC (US) | 2021-03-24 | — | — | EP | claimed |
| US-20200268713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2020-08-27 | — | — | US | claimed |
| US-20180243267-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2018-08-30 | — | — | US | claimed |
| US-20160374991-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-12-29 | — | — | US | claimed |
| EP-3071561-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| US-12268668-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240189281-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | SABRE THERAPEUTICS LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374991-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-11779568-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-20240189281-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-11344533-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-20200268713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-12268668-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
| US-20180243267-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885PKM 4442/4885SGMS2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.